GSK plc shares slid after the drugmaker said it would acquire Nuvalent Inc. in an all-cash transaction valued at $10.6 billion, with GSK paying $124 per Nuvalent share - a 40% premium to Nuvalent's last closing price. The announcement prompted a drop in GSK's stock price, which fell to around 1848p, reflecting investor concern about the transaction's near-term effects on the acquirer's balance sheet.
Net of cash acquired, the deal equates to an investment of approximately $9.4 billion, and it is described as GSK's largest acquisition in more than a decade. The purchase brings three lung cancer-focused assets into GSK's portfolio in one transaction, most notably zidesamtinib and neladalkib, both of which are under review by the U.S. Food and Drug Administration and could potentially reach the market before the end of the year.
GSK's chief executive, Luke Miels, set out the company's strategic case for the transaction, stating that the deal "provides GSK with immediate new sales growth opportunities, improving profit contributions from 2027, and a platform in lung cancer for rapid expansion." The statement frames the acquisition as a way to add near-term revenue potential while also establishing a broader presence in lung cancer.
Despite management's rationale, the market response was negative. Analysts and investors focused on the 40% premium paid for Nuvalent and on the immediate financial implications for GSK, a common reaction when large pharmaceutical deals are announced. In such transactions, the acquirer's stock often absorbs short-term selling pressure as market participants price in the cost of the purchase and the uncertainty of integrating a sizeable acquisition.
The deal announcement coincided with a softer tone in broader markets. The FTSE 100 declined amid continuing geopolitical unease related to a fragile Iran-Israel ceasefire, while the pan-European STOXX 600 managed only a marginal gain. Adding to the cautious environment, market pricing reflected expectations for a 25 basis point interest rate increase from the European Central Bank later in the week - a factor that can act as a headwind for capital-intensive deals in the pharmaceutical sector.
Taken together, a richly priced acquisition announcement, a weakening domestic index, and a hawkish monetary policy backdrop combined to put selling pressure on GSK shares on the day of the disclosure. While Nuvalent's assets offer potential long-term upside to GSK's development pipeline, investors chose to emphasize the immediate balance-sheet impact and the execution risk of integrating a $10.6 billion acquisition.
Market reaction in brief
- GSK announced an all-cash purchase of Nuvalent for $10.6 billion, paying $124 per share - a 40% premium to Nuvalent's previous close.
- Net of cash acquired, the investment is about $9.4 billion and is regarded as GSK's largest deal in over ten years.
- The acquisition adds three lung cancer assets, including zidesamtinib and neladalkib, both currently under FDA review and with the potential to launch before year-end.
The acquisition represents a notable strategic move for GSK, but it also highlights the trade-off between immediate financial strain and potential pipeline expansion. Investors and markets will be watching closely for further detail on integration plans and the clinical and regulatory progress of the acquired assets.